Cardiac Changes in Myeloproliferative Neoplasms
Palabras clave
Abstracto
Descripción
According to worldwide study of prevalence of myeloproliferative neoplasms revealed:
Incidence of polycythemia vera ranged 0.01 to 2.61 per 100.000 population and the prevalence ranging from 0.49 to 46.88 per 100.000 population. Incidence of essential thrombocythemia is 0.21 to 2.27 per 100.000 population, prevalence ranging between 11.00 - 42.51 per 100.000 population.
Primary myelofibrosis incidence is 1.15 -4.99 per 100.000 population and prevalence ranging between 1.76 - 4.05 per 100.000 population.In previous studies, cardiac involvement including coronary arterial thrombosis, myocardial infarction, pulmonary hypertension, asymptomatic pericardial effusion, cardiac tamponade, intractable cardiac failure due to intraventricular stenosis and valvular stenosis that occur in myeloproliferative neoplasms. There is a few number of studies in which cardiac lesions were evaluated in myeloproliferative neoplasms by using transthoracic echocardiography but still inadequate, so we need to understand more about cardiovascular complications in myeloproliferative neoplasms.
fechas
| Verificado por última vez: | 05/31/2017 |
| Primero enviado: | 05/24/2017 |
| Inscripción estimada enviada: | 06/04/2017 |
| Publicado por primera vez: | 06/05/2017 |
| Última actualización enviada: | 06/04/2017 |
| Última actualización publicada: | 06/05/2017 |
| Fecha de inicio real del estudio: | 08/31/2017 |
| Fecha estimada de finalización primaria: | 08/30/2018 |
| Fecha estimada de finalización del estudio: | 02/27/2019 |
Condición o enfermedad
Intervención / tratamiento
Device: Transthorathic echocardiogram
Fase
Grupos de brazos
| Brazo | Intervención / tratamiento |
|---|---|
| Active Comparator: study group patients with myeloproliferative neoplasms and reveal cardiac complications by using echocardiogram, intervention by using transthorathic echocardiography for all patients. | |
| Active Comparator: control group patients with hematological disorders including myeloproliferative neoplasms without cardiac affection by using echocardiogram. Intervention will be in the form of using transthorath echocardiography with all patients to reveal any cardiac abnormalities. | |
| Active Comparator: control group 2 healthy people from the same age and sex will be investigated using echocardiogram. Intervention will be in the form of using transthorathic echocardiography. |
Criterio de elegibilidad
| Sexos elegibles para estudiar | All |
| Acepta voluntarios saludables | si |
| Criterios | Inclusion Criteria: - Diagnostic criteria of myeloproliferative neoplasms. Exclusion Criteria: - Extreme body weight e.g., morbid obesity. - Cardiac disease. - Cerebrovascular disorders. - Diabetes mellitus. - Dyslipidemia. |
Salir
Medidas de resultado primarias
1. number of patients with cardiac complications in myeloproliferative diseases. [30 minutes]
